High JAK2V617F variant allele frequency is associated with coronary artery but not aortic valve calcifications in patients with Philadelphia-negative myeloproliferative neoplasms

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 940 KB, PDF-dokument

Background
Patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) have a higher burden of cardiac calcifications compared to the general population. It is not known whether the JAK2V617F mutation is associated with increased cardiac calcification.

Aim
To investigate if a higher JAK2V617F variant allele frequency (VAF) is associated with severe coronary atherosclerosis and the presence of aortic valve calcification (AVC).

Methods
Patients with MPNs were examined by cardiac computer tomography to establish coronary artery calcium score (CACS) and AVC score. The first VAF after diagnosis was registered. Severe coronary atherosclerosis was defined as a CACS >400 and AVC was defined as an AVC score >0.

Results
Among 161 patients, 137 were JAK2V617F mutation-positive, with a median VAF of 26% (interquartile range 12%–52%). A VAF in the upper quartile range was associated with a CACS >400 [odds ratio (OR) 15.96, 95% confidence interval [CI] 2.13–119.53, p = .0070], after adjustment for cardiovascular risk factors and MPN subtype. An association was not found for the presence of AVC (OR 2.30, 95% CI 0.47–11.33, p = 0.31).

Conclusion
In patients with MPNs, there is a significant association between having a VAF in the upper quartile (>52%), and severe coronary atherosclerosis, defined as a CACS >400. The presence of AVC is not associated with VAF.
OriginalsprogEngelsk
BogserieEuropean Journal of Haematology
Vol/bind111
Udgave nummer3
Sider (fra-til)400-406
Antal sider7
ISSN0902-4441
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This work was supported by Region Sjællands Sundhedsvidenskabelige Forskningsfond (Grant number RSSF2017000654), The A.P Møller Foundation for the Advancement of Medical Science (Grant number 17‐L‐0517), University of Copenhagen Cancer Research Foundation (Grant number 2021‐0004), Fabrikant Einar Willumsens Mindelegat (Grant number 20844469), Direktør Kurt Bønnelycke og hustru Grethe Bønnelyckes Fond (Grant number 10053‐030), Tømrermester Jørgen Holm og hustru Elisa F. Hansens Mindelegat (Grant number 20006‐1952), Aase og Ejnar Danielsens Fond, Trigon Fonden, and A.V. Lyckfeldt og hustrus legat.

Publisher Copyright:
© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.

ID: 367089245